BACKGROUND: It is well established that the prevalence of human papillomavirus (HPV) infection is increased among human immunodeficiency virus (HIV)-positive individuals, but the temporal relationships between these infections are unclear. METHODS: During a South African cervical cancer screening trial, 5595 women 35-65 years of age were followed up for 36 months; 577 women were HIV positive at enrollment, HIV seroconversion occurred in 123 women, and 4895 women remained HIV negative throughout. Tests for high-risk HPV DNA and cytology were performed on cervical samples, and a colposcopy/biopsy was performed at each visit. The effects of early HIV infection on the risk of HPV infection and HPV-related disease were evaluated. RESULTS: Among seroconverters, HPV infection prevalence was 20.3% before seroconversion, 23.6% at seroconversion (P = .4), and 49.1% after seroconversion (P = .01). Seroconverters had significantly lower HPV infection prevalence than women with prevalent HIV infection before and at seroconversion (41.8% and 45.9%, respectively) but had similar HPV infection prevalence to women with prevalent HIV infection after seroconversion (49.4%). HIV seroconversion was associated with newly detected HPV infection (adjusted hazard ratio [AHR], 4.02; 95% confidence interval [CI], 2.26-7.13) and increased risk of low-grade cytological abnormalities (AHR, 2.53; 95% CI, 1.16-5.51) compared with HIV-negative women. CONCLUSION: Detection of HPV infection increases rapidly within the first years after HIV seroconversion, suggesting that mucosal immune dysfunction occurring at an early stage of HIV infection may influence HPV-related diseases.
BACKGROUND: It is well established that the prevalence of human papillomavirus (HPV) infection is increased among human immunodeficiency virus (HIV)-positive individuals, but the temporal relationships between these infections are unclear. METHODS: During a South African cervical cancer screening trial, 5595 women 35-65 years of age were followed up for 36 months; 577 women were HIV positive at enrollment, HIV seroconversion occurred in 123 women, and 4895 women remained HIV negative throughout. Tests for high-risk HPV DNA and cytology were performed on cervical samples, and a colposcopy/biopsy was performed at each visit. The effects of early HIV infection on the risk of HPV infection and HPV-related disease were evaluated. RESULTS: Among seroconverters, HPV infection prevalence was 20.3% before seroconversion, 23.6% at seroconversion (P = .4), and 49.1% after seroconversion (P = .01). Seroconverters had significantly lower HPV infection prevalence than women with prevalent HIV infection before and at seroconversion (41.8% and 45.9%, respectively) but had similar HPV infection prevalence to women with prevalent HIV infection after seroconversion (49.4%). HIV seroconversion was associated with newly detected HPV infection (adjusted hazard ratio [AHR], 4.02; 95% confidence interval [CI], 2.26-7.13) and increased risk of low-grade cytological abnormalities (AHR, 2.53; 95% CI, 1.16-5.51) compared with HIV-negative women. CONCLUSION: Detection of HPV infection increases rapidly within the first years after HIV seroconversion, suggesting that mucosal immune dysfunction occurring at an early stage of HIV infection may influence HPV-related diseases.
Authors: Lynette Denny; Louise Kuhn; Michelle De Souza; Amy E Pollack; William Dupree; Thomas C Wright Journal: JAMA Date: 2005-11-02 Impact factor: 56.272
Authors: Diljeet K Singh; Kathryn Anastos; Donald R Hoover; Robert D Burk; Qiuhu Shi; Louis Ngendahayo; Eugene Mutimura; Antonio Cajigas; Venerand Bigirimani; Xiaotao Cai; Janvier Rwamwejo; Magalis Vuolo; Mardge Cohen; Philip E Castle Journal: J Infect Dis Date: 2009-06-15 Impact factor: 5.226
Authors: Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek Journal: J Exp Med Date: 2004-09-13 Impact factor: 14.307
Authors: Maarten F Schim van der Loeff; Alex Vorsters; Elske Marra; Pierre Van Damme; Arjan Hogewoning Journal: Hum Vaccin Immunother Date: 2019-05-07 Impact factor: 3.452
Authors: Mohak Mhatre; Thomas McAndrew; Colleen Carpenter; Robert D Burk; Mark H Einstein; Betsy C Herold Journal: Sex Transm Dis Date: 2012-08 Impact factor: 2.830
Authors: Aaron A R Tobian; Xiangrong Kong; Maria J Wawer; Godfrey Kigozi; Patti E Gravitt; David Serwadda; Kevin P Eaton; Fred Nalugoda; Thomas C Quinn; Ronald H Gray Journal: Lancet Infect Dis Date: 2011-04-12 Impact factor: 25.071
Authors: Jessica A Kahn; Robert D Burk; Kathleen E Squires; Bill G Kapogiannis; Bret Rudy; Jiahong Xu; René Gonin; Nancy Liu; Carol Worrell; Craig M Wilson Journal: J Acquir Immune Defic Syndr Date: 2012-11-01 Impact factor: 3.731
Authors: Anne F Rositch; Anne E Burke; Raphael P Viscidi; Michelle I Silver; Kathryn Chang; Patti E Gravitt Journal: Cancer Res Date: 2012-09-27 Impact factor: 12.701